咨询与建议

看过本文的还看了

相关文献

该作者的其他文献

文献详情 >Recent progress of aptamer-dru... 收藏

Recent progress of aptamer-drug conjugates in cancer therapy

作     者:Jiaxuan He Qiao Duan Chunyan Ran Ting Fu Yuan Liu Weihong Tan Jiaxuan He;Qiao Duan;Chunyan Ran;Ting Fu;Yuan Liu;Weihong Tan

作者机构:The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital)The Key Laboratory of Zhejiang Province for Aptamers and TheranosticsHangzhou Institute of Medicine(HIM)Chinese Academy of SciencesHangzhou 310022China Molecular Science and Biomedicine Laboratory(MBL)State Key Laboratory of Chemo/Biosensing and ChemometricsCollege of Chemistry and Chemical EngineeringCollege of BiologyAptamer Engineering Center of Hunan ProvinceHunan UniversityChangsha 410082China Institute of Molecular Medicine(IMM)Renji HospitalShanghai Jiao Tong University School of Medicineand College of Chemistry and Chemical EngineeringShanghai Jiao Tong UniversityShanghai 200240China 

出 版 物:《Acta Pharmaceutica Sinica B》 (药学学报(英文版))

年 卷 期:2023年第13卷第4期

页      面:1358-1370页

核心收录:

学科分类:1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基  金:supported by the Zhejiang Provincial Natural Science Foundation of China(No.Y21C050001,China) Zhejiang Provincial Research Center for Diagnosis and Treatment of Major Diseases(No.JBZX-202003,China) the National Natural Science Foundation of China(Nos.22104132 and 22204144) the Zhejiang Province“Kunpeng”Program  

主  题:Aptamer Cancer therapy Aptamer-drug conjugate Drug delivery Small-molecule drug Therapeutic molecules Nucleic acid drugs Biotherapeutic drug 

摘      要:Aptamers are single-stranded DNA or RNA sequences that can specifically bind with the target protein or molecule via specific secondary structures.Compared to antibody-drug conjugates(ADC),aptamer-drug conjugate(ApDC)is also an efficient,targeted drug for cancer therapy with a smaller size,higher chemical stability,lower immunogenicity,faster tissue penetration,and facile engineering.Despite all these advantages,several key factors have delayed the clinical translation of ApDC,such as in vivo off-target effects and potential safety issues.In this review,we highlight the most recent progress in the development of ApDC and discuss solutions to the problems noted above.

读者评论 与其他读者分享你的观点

用户名:未登录
我的评分